Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OKI-179 · 2 trials · 4 indications
| Name | Type | Description |
|---|---|---|
| OKI-179 + binimetinib | DRUG | Phase 1b: With a 3+3 dose escalation design, enrollment in Phase 1b will proceed until the MTD has been defined or the highest dose level has been reached. OKI-179 will be administered on a 4-days-on/3-days-off schedule, while binimetinib will be administered BID continuously. Phase 2: Patients will be treated with the RP2D. |
| OKI-179 | DRUG | OKI-179 single agent |
Top 4 of 6 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Tango Therapeutics, Inc. | TNGX | 1 | PHASE1 | TNG462 |
| Adlai Nortye Ltd. Sponsored ADR | ANL | 2 | PHASE1 | AN9025, AN4035 |
| Pasithea Therapeutics Corp. | KTTA | 1 | PHASE1 | PAS-004 |
| BeOne Medicines Ltd. Sponsored ADR | ONC | 1 | PHASE1 | BG-85738, Tislelizumab |
OKI-179 is an investigational small molecule developed by OnKure Therapeutics, Inc. (ticker OKUR) for advanced solid tumors, including cancers with RAS pathway mutations. It is a Class I HDAC inhibitor and has been studied in Phase 1 and Phase 1b/2 clinical trials, both of which are now completed.
OKI-179 targets HDAC, specifically Class I histone deacetylases. As a Class I HDAC inhibitor, it is designed to interfere with HDAC enzyme activity in tumor cells. It has been evaluated in advanced solid tumors and RAS-mutated cancers, including in combination with the MEK inhibitor binimetinib.
OKI-179 is developed by OnKure Therapeutics, Inc., which trades under the ticker OKUR. The company has sponsored the clinical studies of OKI-179, including the Phase 1 study in solid tumors and the Phase 1b/2 NAUTILUS study of OKI-179 plus binimetinib.
OKI-179 is in Phase 1 development. It has been tested in a Phase 1 study and a Phase 1b/2 study, both of which are completed. OKI-179 is investigational and has not been approved by the FDA for any indication.
OKI-179 has been studied in two completed trials. NCT03931681 was a Phase 1 study of OKI-179 in patients with solid tumors, enrolling 34 participants. NCT05340621, called NAUTILUS, was a Phase 1b/2 study of OKI-179 plus binimetinib in advanced solid tumors in the RAS pathway and NRAS-mutated melanoma, enrolling 36 participants.